KRAS-targeted TCR-T therapy with dominant negative TGF-β receptor
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for KRAS-targeted TCR-T therapy with dominant negative TGF-β receptor, covering 2026-03-16 to 2026-03-16. Get the full timeline:
Most recent: Clinical Trial Update: T Cell Receptor Gene-Engineered and Dominant Negative TGF-β Receptor T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor [Phase 1]